Osteosarcomas in retinoblastoma-survivors. A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)

Autor: Stefan S. Bielack, Daniel Baumhoer, Stefanie Hecker-Nolting, Simone Hettmer, Leo Kager, Petra Ketteler, Matthias Kevric, Christian P. Kratz, Thomas Kühne, Vanessa Mettmann, Markus Metzler, Dirk Reinhardt, Benjamin Sorg, Claudia Blattmann

Publikováno v: EJC Paediatric Oncology, Vol 3, Iss , Pp 100158- (2024)

Purpose: Many publications address the epidemiology of secondary osteosarcomas following retinoblastoma. Treatment- and outcome-related information is, however, scarce. We used a large cooperative group’s database to study this issue. Patients and

Externí odkaz: https://doaj.org/article/ebd3c9a7340c4a5fb601494f01178b43

Planning preclinical confirmatory multicenter trials to strengthen translation from basic to clinical research – a multi-stakeholder workshop report

Autor: Natascha Ingrid Drude, Lorena Martinez-Gamboa, Meggie Danziger, Anja Collazo, Silke Kniffert, Janine Wiebach, Gustav Nilsonne, Frank Konietschke, Sophie K. Piper, Samuel Pawel, Charlotte Micheloud, Leonhard Held, Florian Frommlet, Daniel Segelcke, Esther M. Pogatzki-Zahn, Bernhard Voelkl, Tim Friede, Edgar Brunner, Astrid Dempfle, Bernhard Haller, Marie Juliane Jung, Lars Björn Riecken, Hans-Georg Kuhn, Matthias Tenbusch, Lina Maria Serna Higuita, Edmond J. Remarque, Servan Luciano Grüninger-Egli, Katrin Manske, Sebastian Kobold, Marion Rivalan, Lisa Wedekind, Juliane C. Wilcke, Anne-Laure Boulesteix, Marcus W. Meinhardt, Rainer Spanagel, Simone Hettmer, Irene von Lüttichau, Carla Regina, Ulrich Dirnagl, Ulf Toelch

Publikováno v: Translational Medicine Communications, Vol 7, Iss 1, Pp 1-13 (2022)

Abstract Clinical translation from bench to bedside often remains challenging even despite promising preclinical evidence. Among many drivers like biological complexity or poorly understood disease pathology, preclinical evidence often lacks desired

Externí odkaz: https://doaj.org/article/bf47b97f5e2949fb928a3da8d60cd224

Breast cancer characteristics and surgery among women with Li‐Fraumeni syndrome in Germany—A retrospective cohort study

Autor: Nathalie Rippinger, Christine Fischer, Hans‐Peter Sinn, Nicola Dikow, Christian Sutter, Kerstin Rhiem, Sabine Grill, Friedrich W. Cremer, Huu P. Nguyen, Nina Ditsch, Karin Kast, Simone Hettmer, Christian P. Kratz, Sarah Schott

Publikováno v: Cancer Medicine, Vol 10, Iss 21, Pp 7747-7758 (2021)

Abstract Background Women with Li‐Fraumeni syndrome (LFS) have elevated breast cancer (BC) risk. Optimal BC treatment strategies in this population are yet unknown. Methods BC subtypes and treatment were retrospectively investigated between Decembe

Externí odkaz: https://doaj.org/article/82b6f656edef42f591c23cc2099cf361

Myxoid liposarcoma: it's a hippo's world

Autor: Carla Regina, Simone Hettmer

Publikováno v: EMBO Molecular Medicine, Vol 11, Iss 5, Pp 1-3 (2019)

Abstract Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann et al in this issue of EMBO Molecular Medicine utilizes a dr

Externí odkaz: https://doaj.org/article/0d15cfd0238d4d53a606cf439bc86840

Community-driven development of a modified progression-free survival ratio for precision oncology

Autor: Sebastian Schölch, Benedikt Brors, Albrecht Stenzinger, Ursula Ehmer, Ulrich-Frank Pape, Christoph Springfeld, Dirk Jäger, Felix J Hüttner, Andreas Mock, Christoph E Heilig, Simon Kreutzfeldt, Daniel Huebschmann, Christoph Heining, Evelin Schröck, Richard Schlenk, Hanno Glimm, Stefan Fröhling, Peter Horak, Leonidas Apostolidis, Marinela Augustin, Daniela Aust, Irfan Ahmed Bhatti, Johannes Bloehdorn, Cornelia Brendel, Christian Britschgi, Jan Braess, Stefan Burdach, Elena Busch, Jozefina Casuscelli, Alexander Desuki, Thomas Deutsch, Mareike Dietrich, Thomas J Ettrich, Johanna Falkenhorst, Tanja Fehm, Anne Flörcken, Andrea Forschner, Stefan Fuxius, Maria Gonzales-Carmona, Frank Griesinger, Sabine Grill, Stefan Gröschel, Georg Martin Haag, Ulrich Haag, Niels Halama, Holger Hebart, Nina Heidger, Barbara Hermes, Georg Hess, Simone Hettmer, Manuela Hoechstetter, Martin Hoffmann, Anna L Illert, Maximilian Jenzer, Bernd Kasper, Stefan Kasper-Virchow, Thomas Kindler, Ewa Koscielniak, Jan Krönke, Michael Kühn, Volker Kunzmann, Alois Lang, Jonas Leichsenring, Elisabeth Livingstone, Lucia Liotta, Kim Luley, Elisabeth Mack, Uwe M Martens, Klaus Metzeler, Jan Moritz Middeke, Lino Möhrmann, Roopa Jayarama-Naidu, Lukas Perkhofer, Arne Pfeufer, Constantin Pixberg, Michael Quante, Bernhard Rendenbach, Damian Rieke, Christian Rothermundt, Andre Norbert Sagerer, Martin Salzmann, Dieter Saur, Bastian Schilling, Jan Schleicher, Anke Schlenska-Lange, Thomas Schmidt, Sophia Schmitz, Rajiv Shah, Khalid Shoumariyeh, Alexander Siebenhüner, Martin Singh, Jens Siveke, Helen Starke, Sophia Strobel, Veronica Teleanu, Niklas Thon, Sebastian Wagner, Thomas Walle, Benedikt Westphalen, Bettina Whitlock, Eva Winkler, Naita Maren Wirsik, Lena Woydack, Angelika Zabel-du Bois, Stefanie Zschäbitz

Publikováno v: ESMO Open, Vol 4, Iss 6 (2019)

Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecul

Externí odkaz: https://doaj.org/article/0122f1ac148444cbaeb951db5af876a5